BR112016012580A8 - quimera de antígeno, composição de antígeno, vacina, método de preparação da mesma e cassete da mesma. - Google Patents
quimera de antígeno, composição de antígeno, vacina, método de preparação da mesma e cassete da mesma.Info
- Publication number
- BR112016012580A8 BR112016012580A8 BR112016012580A BR112016012580A BR112016012580A8 BR 112016012580 A8 BR112016012580 A8 BR 112016012580A8 BR 112016012580 A BR112016012580 A BR 112016012580A BR 112016012580 A BR112016012580 A BR 112016012580A BR 112016012580 A8 BR112016012580 A8 BR 112016012580A8
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- multimer
- immune adjuvant
- mucosal immune
- chimera
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
resumo da patente de invenção para: ?quimera de antígeno, composição de antígeno, vacina, método de preparação da mesma e cassete da mesma?. a presente invenção fornece uma quimera de antígeno, que compreende: uma proteína de fusão de um antígeno e um monômero de proteína adjuvante imune da mucosa capaz de formar um multímero; e o monômero de proteína adjuvante imune da mucosa capaz de formar um multímero; em monômero de proteína adjuvante imune da mucosa capaz de formar um multímero é um selecionado a partir da subunidade b da toxina da cólera (ctb) e da subunidade b da enterotoxina termo-lábil (ltb) de e. coli, o multímero é um pentâmero, e na quimera a razão molar entre a proteína de fusão monômero de proteína adjuvante imune da mucosa capaz de formar um multímero é de 1: 4. na presente invenção, uma característica que uma proteína adjuvante imune da mucosa pode formar um pentâmero é usada para formar uma estrutura quimérica, de modo a formar um antígeno possuindo uma potência mais elevada. além disso, uma proteína adjuvante imune da mucosa é usada para melhorar um efeito imune de modo a melhorar um efeito de aumentar a imunogenicidade do antígeno. além disso, o antígeno de proteína quimérica formado com o antígeno recombinado da presente invenção estimula uma membrana mucosa a produzir iga secretora e induz a ocorrência da imunidade da mucosa.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310655338.6 | 2013-12-06 | ||
| CN201310655338 | 2013-12-06 | ||
| CN201410217707.8 | 2014-05-20 | ||
| CN201410217707.8A CN103990121B (zh) | 2013-12-06 | 2014-05-20 | 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒 |
| PCT/CN2014/083291 WO2015081711A1 (zh) | 2013-12-06 | 2014-07-30 | 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016012580A2 BR112016012580A2 (pt) | 2017-09-26 |
| BR112016012580A8 true BR112016012580A8 (pt) | 2018-01-23 |
| BR112016012580B1 BR112016012580B1 (pt) | 2020-12-15 |
Family
ID=51304617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016012580-0A BR112016012580B1 (pt) | 2013-12-06 | 2014-07-30 | Quimera de antígeno, composição de antígeno, vacina, método de preparação da mesma e cassete da mesma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10513543B2 (pt) |
| EP (1) | EP3078677B1 (pt) |
| JP (1) | JP6316448B2 (pt) |
| KR (1) | KR101973079B1 (pt) |
| CN (1) | CN103990121B (pt) |
| AU (1) | AU2014360050B2 (pt) |
| BR (1) | BR112016012580B1 (pt) |
| CA (1) | CA2932211C (pt) |
| WO (1) | WO2015081711A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104962541A (zh) * | 2015-03-31 | 2015-10-07 | 芜湖康卫生物科技有限公司 | 口服重组幽门螺杆菌疫苗的纯化工艺 |
| CN105462997A (zh) * | 2015-12-23 | 2016-04-06 | 江南大学 | 一种新脲酶辅基基因及其应用 |
| PL3512537T3 (pl) * | 2016-09-15 | 2024-02-26 | Elicera Therapeutics Ab | Immunoterapia limfocytami t |
| CN109010820B (zh) * | 2018-08-31 | 2021-11-02 | 中国人民解放军陆军军医大学 | 植物多糖在黏膜免疫佐剂中的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4623625B2 (ja) | 2003-07-24 | 2011-02-02 | 株式会社ＡＭＢｉＳ | ヘテロ型５量体組換えワクチン |
| EP1522585A1 (en) * | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
| CN1255542C (zh) | 2004-03-29 | 2006-05-10 | 中国人民解放军第三军医大学 | 融合型幽门螺杆菌粘附素基因工程疫苗的制备方法 |
| US20080274143A1 (en) | 2005-05-27 | 2008-11-06 | Henry Daniell | Chloroplasts Engineering to Express Pharmaceutical Proteins |
| CN100460013C (zh) * | 2006-09-05 | 2009-02-11 | 重庆康卫生物科技有限公司 | 口服重组幽门螺杆菌疫苗及其制备方法 |
| CN1973903A (zh) | 2006-12-04 | 2007-06-06 | 严杰 | 预防幽门螺杆菌感染的基因重组口服疫苗及其制备方法 |
| CN101036786A (zh) * | 2007-02-02 | 2007-09-19 | 中国药科大学 | 一种免佐剂具有治疗动脉粥样硬化作用的免疫调节剂 |
| CN101062015A (zh) * | 2007-05-22 | 2007-10-31 | 中国药科大学 | 抗幽门螺杆菌感染的尿素酶表位融合肽脂质体疫苗 |
| WO2010092963A1 (ja) * | 2009-02-10 | 2010-08-19 | 国立大学法人 琉球大学 | 薬物運搬体並びにこれを利用したアジュバントおよびワクチン |
| CN101987873A (zh) | 2009-08-07 | 2011-03-23 | 普罗特奥姆技术公司 | P53融合蛋白及应用 |
| CN102260353A (zh) * | 2010-05-28 | 2011-11-30 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| CN102675466A (zh) | 2011-03-09 | 2012-09-19 | 冯强 | 以大肠杆菌不耐热肠毒素b亚单位为载体的表位递送系统 |
| CN102151332A (zh) | 2011-03-22 | 2011-08-17 | 中国药科大学 | 一种幽门螺旋杆菌表位疫苗及其设计、制备方法和应用 |
| CA2849374A1 (en) * | 2011-09-23 | 2013-03-28 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| CN103127498A (zh) * | 2011-12-02 | 2013-06-05 | 上海联合赛尔生物工程有限公司 | 重组抗原组合物、疫苗、制备该抗原组合物的载体和方法 |
| CN102604993B (zh) * | 2012-01-10 | 2013-03-20 | 天津耀宇生物技术有限公司 | 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法 |
-
2014
- 2014-05-20 CN CN201410217707.8A patent/CN103990121B/zh active Active
- 2014-07-30 AU AU2014360050A patent/AU2014360050B2/en active Active
- 2014-07-30 JP JP2016557173A patent/JP6316448B2/ja active Active
- 2014-07-30 WO PCT/CN2014/083291 patent/WO2015081711A1/zh active Application Filing
- 2014-07-30 KR KR1020167018064A patent/KR101973079B1/ko active IP Right Grant
- 2014-07-30 BR BR112016012580-0A patent/BR112016012580B1/pt active IP Right Grant
- 2014-07-30 EP EP14868697.5A patent/EP3078677B1/en active Active
- 2014-07-30 US US15/102,125 patent/US10513543B2/en active Active
- 2014-07-30 CA CA2932211A patent/CA2932211C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160368951A1 (en) | 2016-12-22 |
| JP6316448B2 (ja) | 2018-04-25 |
| AU2014360050A1 (en) | 2016-07-07 |
| CA2932211C (en) | 2019-08-27 |
| KR20160093719A (ko) | 2016-08-08 |
| CA2932211A1 (en) | 2015-06-11 |
| US10513543B2 (en) | 2019-12-24 |
| AU2014360050B2 (en) | 2017-11-02 |
| JP2017504655A (ja) | 2017-02-09 |
| WO2015081711A1 (zh) | 2015-06-11 |
| BR112016012580A2 (pt) | 2017-09-26 |
| BR112016012580B1 (pt) | 2020-12-15 |
| CN103990121A (zh) | 2014-08-20 |
| EP3078677B1 (en) | 2022-04-06 |
| CN103990121B (zh) | 2015-07-08 |
| EP3078677A1 (en) | 2016-10-12 |
| EP3078677A4 (en) | 2017-10-18 |
| KR101973079B1 (ko) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015001390A2 (pt) | vacina de proteína de fusão multimérica e imunoterápicos | |
| BR112016012580A8 (pt) | quimera de antígeno, composição de antígeno, vacina, método de preparação da mesma e cassete da mesma. | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BR112015014723A2 (pt) | método cromatográfico de isolamento e purificação de albumina de soro humano recombinante de alta pureza | |
| BR112015015523A2 (pt) | composição de vacina nasal para influenza | |
| BR112018075785A2 (pt) | formulação de vacina para o hiv | |
| CO5700790A2 (es) | Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina | |
| BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
| BR112015009541A2 (pt) | novos adjuvantes de mucosa e sistemas de aplicação | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| AU2014232363A8 (en) | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom | |
| JP2013518052A5 (pt) | ||
| BR112019007803A2 (pt) | formulações de vacina de glicoconjugado contra expec | |
| BR112015018335A2 (pt) | Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas | |
| BR112016028418A2 (pt) | composição de adjuvante, vacina, anticorpo agonista cd40 ou uma parte desse, composição farmacêutica, construto, célula, e, método de mapeamento de epítopo de um polipeptídeo | |
| CO6561819A2 (es) | Vectores para vacunas y método para potenciar respuestas inmunes | |
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| JP2015529677A5 (pt) | ||
| Chitradevi et al. | Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection | |
| BR112012022059A8 (pt) | Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa | |
| HRP20180039T1 (hr) | Antigeni pseudomonasa i kombinacije antigena | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| BR112018013501A2 (pt) | uso de um ingrediente fermentado e oligossacarídeo não digerível na manufatura de uma composição nutricional, método para aumento de secreção de imunoglobulina a em um indivíduo humano com idade de 0 a 36 e método para melhorar a defesa imunológica da mucosa em um indivíduo humano com idade de 0 a 36 meses | |
| CR9269A (es) | Vacunas orales para peces |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2014, OBSERVADAS AS CONDICOES LEGAIS. |